Polysomy detected by fl uorescence in situ hybridization (FISH) is associated with cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC). However, a subset of PSC patients with polysomy do not manifest CCA even after long-term follow-up. It is unknown if patients with chromosomal gains detected by FISH in multiple areas of the biliary tree (i.e., multifocal polysomy, MFP) are more likely to be diagnosed with CCA than patients with unifocal polysomy (UFP). Therefore, our aim is to determine whether patients with MFP are more likely to manifest CCA compared with patients with other chromosomal abnormalities including UFP and other FISH subtypes.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic liver disorder characterized by infl ammation and fi brosis of the intra and/or extrahepatic bile ducts, which leads to cholestasis, liver injury, and fi brosis ( 1 ) . Cholangiocarcinoma (CCA) may develop in 5-10% of patients with PSC and it may arise from a background of premalignant biliary tissue (fi eld defect) including dysplasia ( 2, 3 ) . Although CCA is associated with a poor prognosis, a multicenter study reported a 72% 5-year survival free of CCA recurrence among PSC patients with early-stage CCA who undergo neoadjuvant chemoradiation followed by a liver transplant ( 4 ) . Th erefore, early detection of CCA is important as a subset of PSC patients will be eligible for curative therapy.
Distinguishing benign from malignant biliary strictures in PSC is challenging and the sensitivity of conventional biliary cytology is <45% ( 5 ) . Although the presence of a malignant mass lesion with delayed venous phase enhancement on imaging is highly sensitive and specifi c for CCA, such lesions are uncommon in earlystage CCA ( 6, 7 ) . While an elevated carbohydrate antigen 19-9 (CA 19-9) is concerning for CCA, not all PSC patients with an elevated CA 19-9 will have biliary cancer (8) (9) (10) (11) . Advanced endoscopic techniques such as narrow-band imaging cholangioscopy have a highly variable appearance in PSC and do not appear to reliably increase the rate of biliary neoplasia detection ( 12 ) . Th erefore, complementary techniques such as fl uorescence in situ hybridization (FISH) to assess for chromosomal aneuploidy (losses or gains of chromosomes) are used to assist in CCA detection ( 13 ) . Polysomy has been associated with CCA ( 8, 14, 15 ) . However, CCA may be absent in up to 45% of PSC patients with polysomy detected on a single exam ( 14 ) . In contrast, CCA has been detected in up to 69% of PSC patients when polysomy is detected on subsequent examinations (serial polysomy) ( 15 ) .
Because only a subset of PSC patients with polysomy will be diagnosed with CCA, it is important to identify other features that can predict the diagnosis of CCA once polysomy is detected to enhance our ability to risk stratify these patients. It is unknown if patients with multifocal polysomy (MFP) are at a higher risk of CCA compared with those with polysomy in a single location in the biliary tree (i.e., unifocal polysomy, UFP). Consequently, our primary aim is to determine if PSC patients with MFP detected on a single exam are more likely to be diagnosed with CCA compared with patients with UFP and other FISH types (serial polysomy, trisomy/tetrasomy, or a negative FISH study). Our secondary aim is to examine key clinical diff erences between those with UFP and MFP.
METHODS

Patients
Th is study was approved by the Institutional Review Board at Mayo Clinic, Rochester, Minnesota, USA. We performed a retrospective review of all patients with PSC who underwent crosssectional imaging and biliary brushings for cytology and FISH who were seen at our institution between 1 January 2005 to 1 July 2013. Th e initial cohort was established by searching the electronic medical record system for patients with the term "primary sclerosing cholangitis" or "PSC" anywhere in their medical record and cross matched with those who had biliary brushings for FISH performed. Th e electronic medical records of this initial cohort were reviewed in detail.
Patients were included if the following were present: (i) retrograde, percutaneous or magnetic resonance cholangiography (MRC) demonstrating typical features of PSC including multifocal intrahepatic and/or extrahepatic biliary duct obstruction, beading or narrowing consistent with PSC; (ii) FISH was performed on biliary brushings obtained at the time of an endoscopic retrograde cholangiogram (ERC) or percutaneous transhepatic cholangiogram; and (iii) had cross-sectional abdominal imaging available for review. Patients were excluded from the primary analyses if one of the following were present: (i) history of a liver transplant, CCA, or gallbladder malignancy before the index FISH; (ii) gallbladder cancer or any intrahepatic malignancy (excluding CCA) at the time of index FISH; (iii) defi nitive radiographic features of CCA (mass lesion) seen at time of index FISH; or (iv) patients with polysomy who only had a single brushing performed and could not be classifi ed as either UFP or MFP. Th e index FISH was defi ned as the most severe FISH result that occurred fi rst. MFP was considered the most severe FISH subtype followed by UFP, trisomy, or tetrasomy and a negative FISH. If a patient only had negative FISH results, then the earliest FISH test was identifi ed as the index FISH.
For CCA screening, it is our clinical practice to obtain liver tests every 3-6 months, an annual CA 19-9 and annual abdominal imaging (ultrasound or MRC) in all PSC patients. We will typically perform an ERC if patients develop clinical symptoms to suggest biliary obstruction, suspicious fi ndings on imaging (including a dominant stricture), or worsening laboratory tests (including CA 19-9 elevations). Patients with suspicious fi ndings will be followed closely with repeat imaging and/or ERC with brushings. Bile duct biopsies may also be obtained during ERC, if anatomically possible.
Data collection and key defi nitions
Data were obtained through the electronic medical record and abstracted on a standardized template. In addition to demographic features, the indication for undergoing a cholangiogram with FISH testing, cholangiography features, cytopathology data, the presence of symptoms, laboratory values (within 3 months of the index FISH), revised Mayo PSC risk, MELD and Child Pugh scores (16) (17) (18) and imaging features were abstracted at the time of the cholangiogram when the index FISH was identifi ed. If a particular variable was not available for a patient, that individual was not included in the analysis for that missing covariate. A CA 19-9 ≥129 U/ml was selected as the cutoff on the basis of prior studies ( 8 ) . Treating CA 19-9 as a continuous variable did not impact our results (data not shown). All patients underwent cross-sectional imaging (typically MRC) within 3 months of the index FISH.
Th e primary end point was CCA. CCA was defi ned as the presence of adenocarcinoma on cytology or biopsy specimens or a mass lesion with typical features of CCA seen on cross-sectional imaging (with or without metastases) ( 7 ) . Imaging features considered indeterminate for CCA include bile duct wall thickening, irregularity or enhancement, marked biliary dilation, the presence of a dominant stricture, or focal biliary dilation with ipsilateral lobe atrophy. A dominant stricture is typically defi ned as a stricture with a diameter 1 mm or less in the hepatic duct or 1.5 mm or less in the common bile duct; determination of the presence of a dominant stricture was made by the endoscopist performing the ERC at the time of the index FISH ( 7 ). When dominant strictures are encountered, a wire-guided cytology brush is passed back and forth through the stricture repeatedly. Dominant strictures at distinct locations (right and left hepatic ducts, hilum, the common hepatic and common bile duct) are typically brushed separately and placed in diff erent vials. If feasible, it is also our practice to brush irregular segments of the central bile ducts or areas that appeared thickened or showed enhancement on a MRC. Th e contents of each vial are split equally for routine cytology and FISH as previously described ( 15 ) .
For conventional cytology, each patient specimen was evaluated by an experienced cytopathologist using standardized criteria and categorized as one of the following: inadequate cellularity, negative,
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Biliary MFP and CCA in PSC Patients atypical, suspicious for adenocarcinoma, or positive for adenocarcinoma ( 19, 20 ) . FISH was performed with the UroVysion probe set (Abbott Molecular, Des Plaines, IL, USA) and specimens containing thousands of cells were assessed as previously described and categorized as either negative, trisomy, tetrasomy, or polysomy ( Figure 1 , ( refs 14,15 ) . One hundred consecutive epithelial cells from specimens categorized as polysomy were reviewed to generate an estimated proportion of cells positive for polysomy.
Patients with a negative FISH study, trisomy, or tetrasomy were included in the study regardless of the number of areas brushed. Patients were considered candidates for either UFP or MFP if brushings were performed in more than one location of the biliary tree during a single procedure and the specimens from diff erent locations were placed in separate vials. If such patients had only one area positive for polysomy they were considered to have UFP, whereas MFP patients had polysomy detected in brushings from two or more areas. In contrast, if a patient had only a single area brushed which was positive for polysomy, they were defi ned as indeterminate for UFP or MFP and excluded from the primary analyses. Serial polysomy is defi ned as more than one FISH test positive for polysomy on more than one procedure ( 15 ) .
Statistical analysis
All patients were analyzed on the basis of their index FISH results (i.e., negative, trisomy/tetrasomy, UFP, or MFP). Analysis was performed utilizing SAS 9.3 (SAS Institute; Cary, NC) and R 3.0.2 (R Foundation for Statistical Computing; Vienna, Austria). All tests were two-sided with a level of signifi cance of P <0.05. Categorical data were compared using the Pearson chi-squared test and continuous variables were compared using the KruskalWallis test. Continuous variables are expressed as median interquartile range (IQR). Follow-up was calculated from the time of the index FISH to the time of CCA diagnosis or censoring. Th e patients without CCA were censored at the time of liver transplantation and if this did not occur, then at their last cholangiogram or cross-sectional image (whichever occurred last). Th e Kaplan-Meier method was used to plot the survival free curves of the primary end point between FISH groups. Th e cumulative incidence of CCA was determined by the one minus KaplanMeier method. Cox proportional hazards regression analysis was utilized in both univariable and multivariable analyses to examine associations between covariates and the primary end point, and the results were expressed as hazard ratios (HRs) with respective 95% confi dence intervals (CIs). Serial polysomy was treated as a time-dependent covariate, recognizing that this designation was oft en not determined until aft er the index FISH (baseline). Examination of the Schoenfeld residuals was used to check the proportional hazards assumptions. To avoid overfi tting of our multivariable model, covariates associated with CCA ( P value <0.05) in the univariable analysis were included in the multivariable model as individual covariates plus the FISH subtype. As shown by Vittinghoff and McCulloch, the number of covariates included in our models is appropriate and would not be expected to cause model instability ( 21 ) .
RESULTS
Patients
During the 7.5-year study period, an estimated 3,100 unique patients with a diagnosis of PSC were seen at our institution. Among these individuals, 545 patients underwent FISH testing ( Figure 2 ). Th e most common indication for exclusion from this study was defi nitive evidence of CCA seen on cross-sectional imaging at the time of the index FISH ( n =107). Twenty-six patients with polysomy had only a single brushing performed and were therefore indeterminate for UFP or MFP. Ultimately, 371 patients (all with large duct PSC) were included in the primary analyses (negative FISH n =194, trisomy or tetrasomy n =114, UFP n =32, MFP n =31).
Th e majority of patients underwent FISH testing due to a concern for CCA. Th is concern was raised by a varied clinical presentation, which typically suggested worsening biliary obstruction ( Table 1 ). Weight loss was more common among those with MFP compared with UFP (32 vs. 9%, P =0.03). Th e most common suspicious imaging feature was a dominant stricture (61%). Although patients with polysomy were more likely to have a prior history of an abnormal FISH result (trisomy/tetrasomy or UFP among MFP patients) or cytology (suspicious or atypical), the proportion of UFP and MFP patients with a history of an abnormal FISH or cytology was similar ( Table 1 ) . Indeed, six patients initially had UFP but were subsequently found to have MFP aft er a median 
Baseline features and diagnosis of serial polysomy
Baseline features between the FISH groups are shown in Table 2 . Infl ammatory bowel disease (IBD) was present in 78% of patients (ulcerative colitis n =245, Crohn's disease n =39, indeterminate colitis n =4). Although patients with MFP appeared to have a longer duration of infl ammatory bowel disease compared with other FISH subtypes, this was not signifi cant when compared with UFP patients. Twenty-eight patients with ulcerative colitis had medically refractory infl ammatory bowel disease which required a colectomy. However, this was not associated with a diagnosis of CCA (HR, 1.98; 95% CI, 0.73-4.53). At baseline, patients with MFP were more likely than patients with UFP to have suspicious cytology (45 vs. 13%, P <0.001) and a higher proportion of cells with polysomy (13 vs. 3%, P <0.001). In contrast, a negative cytology was less common in MFP compared with UFP (7 vs. 47%, P <0.001). Laboratory testing, including CA 19-9 levels, were similar between those with UFP and MFP ( Table 2 ) . Among the MFP and UFP patients with suspicious cytology, the proportion with multifocal, compared with unifocal suspicious cytology was similar between MFP and UFP patients (75 vs. 79%, P =0.88), respectively. Among the 63 patients with polysomy at baseline, 55 had more than one examination and serial polysomy was subsequently detected in 91% (20/22) and 35% (8/23) of patients diagnosed with MFP and UFP (respectively) at baseline ( P <0.001).
Importantly, the prevalence of dominant strictures was similar across all groups and the number of areas sampled was similar for UFP and MFP patients ( Table 1 ). In addition, there were no diff erences between the number of dominant strictures present between UFP and MFP patients: 2 (1-2) vs. 1 (1-2), P =0.23, respectively. Among those with either UFP or MFP and a dominant stricture, polysomy was detected from the site of the dominant stricture in the majority of patients (71% UFP and 92% MFP, P =0.24). However, polysomy was also frequently collected from areas beyond a dominant stricture. For example, 29% of UFP patients and 58% of MFP patients ( P =0.21) had polysomy detected from sites not associated with a dominant stricture.
Diagnosis of cholangiocarcinoma
CCA was detected in 37 patients (negative FISH n =3, trisomy/ tetrasomy n =5, UFP n =6, MFP n =23). Th e 1-and 3-year cumulative incidence (95% CI) of CCA of the entire cohort was 8% (6-12%) and 11% (8-15%), respectively. Ultimately, metastatic CCA and death secondary to CCA occurred in 16 (negative FISH n =2, trisomy/tetrasomy n =1, UFP n =4, MFP n =9) and 14 (negative FISH n =2, trisomy/tetrasomy n =1, UFP n =4, MFP n =7) patients, respectively. Th e diagnosis of CCA was established on the basis of the following: cytology or biopsy alone n =21, defi nitive radiographic features alone n =4, both cytology or biopsy and defi nitive radiographic features n =12.
Brushings positive for adenocarcinoma were detected at the time of the index FISH in 12 patients ( Table 2 ) . Among these 12 patients, 5 (42%) had a dominant stricture identifi ed on the ERC at the time of the index FISH. Polysomy was frequently detected from additional locations other than those with cytology-proven CCA. For example, among UFP and MFP patients with a brushing positive for adenocarcinoma (at any time point), 71% had polysomy detected at another region where adenocarcinoma was not detected on routine cytology.
Patients with MFP were more likely to be diagnosed with CCA in contrast to those with negative FISH, trisomy or tetrasomy, and UFP ( Figure 3 ) . Th e 1-and 3-year cumulative incidence (95% CI) of CCA among MFP patients was 65% (46-81%) and 83% (62-93%), respectively. Aft er including those who were indeterminate for either MFP or UFP, MFP continued to be the strongest FISH predictor of CCA ( Supplementary Figure 1 online) . In addition, MFP remained predictive of a CCA diagnosis aft er excluding those patients with a biopsy or cytology positive for adenocarcinoma at the time of the index FISH ( Supplementary Figure 2 ) . Th e median (IQR) time to CCA diagnosis among those without adenocarcinoma on the index FISH and MFP was 146 (57-357) days.
In the univariable analysis, a prior abnormal FISH (trisomy/ tetrasomy or UFP among those who developed MFP) or prior abnormal cytology (atypical or suspicious), CA 19-9 ≥129 U/ ml, the number of areas sampled at the time of the index FISH, presence of a dominant stricture, atypical cytology, suspicious cytology, UFP, MFP, serial polysomy, and the proportion of cells positive for polysomy were associated with CCA ( Table 3 ). As shown in Figure 4 , MFP and UFP (compared with negative FISH) remained strong predictors of CCA aft er adjustment for the indi- When only patients with polysomy were included in the multivariable analysis, MFP (compared with UFP) remained a predictor of CCA even aft er adjusting for polysomy-specifi c covariates Eaton et al. 
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Th e observations of this study re-inforce the role of FISH in risk stratifying PSC patients and improve our ability to interpret the results of FISH studies when managing individuals with PSC. Th e primary benefi t of performing FISH is improving the sensitivity of CCA detection when compared with routine cytology alone ( 14 ) . In a prior study, the overall proportion of patients with polysomy with CCA was 55% ( 14 ) . However, when polysomy was detected in the context of a dominant stricture or serial polysomy aft er 3 years of follow-up, the proportion of patients with CCA was 73 and 69%, respectively ( 14, 15 ) . By comparison, the 3-year cumulative incidence of CCA among patients with MFP detected on a single exam was 83% regardless if they had a dominant stricture or developed serial polysomy. An elevated CA 19-9 plus polysomy is suspicious for malignancy. For example, a prior study noted 100% (10/10) patients with polysomy, atypical or suspicious cytology, and a CA 19-9 ≥129 U/ml were diagnosed with CCA ( 8 ) . However, an elevated CA 19-9 was not an independent predictor of CCA in the current study. Indeed, several studies have reported that nearly onethird of PSC patients (with and without polysomy) and a CA 19-9 >129 U/ml do not have underlying malignancy ( 10, 11 ) . In the present study, we focus on PSC patients with polysomy FISH result(s) when multiple biliary sites were sampled in a single exam. In this context, MFP was the strongest predictor of CCA. Th e increased proportion of other concerning features among MFP patients such as weight loss, suspicious cytology, indeterminate imaging fi ndings, and serial polysomy also suggests that MFP diff ers from other FISH fi ndings including UFP. Th erefore, patients with MFP should be considered a distinct subgroup of PSC patients at higher risk for CCA. However, patients with UFP and suspicious cytology are also at an increased risk and should not be ignored.
Th ese fi ndings have several clinical implications, which raise new questions. First, these data highlight the importance of obtaining brush cytology from the bile ducts of PSC patients who are undergoing an ERC for suspected CCA, even in those without a dominant stricture, and placing the specimens obtained from diff erent locations into separate vials to determine if MFP is present. We observed that polysomy is frequently found in areas not associated with a dominant stricture and the presence of a dominant stricture was not more common in MFP patients or an independent predictor of CCA. Th is fi nding may be secondary to several factors. Although the presence of a dominant stricture should raise concern for CCA, cancer (particularly early stage) may not always appear as a dominant stricture on a cholangiogram. For example, of the 12 patients with a biliary cytology positive for adenocarcinoma detected at the time of the index FISH, only 42% had a dominant stricture. In addition, a previous study noted that only one-quarter of dominant strictures were associated with malignancy, which also suggests that many dominant strictures are benign ( 22 ) . Th us, not all dominant strictures are malignant and not all cases of cancer present as a dominant stricture. However, CCA that appears as a dominant stricture may represent a more advanced stage of cancer. For example, in a prior study of 21 patients with CCA associated with a CCA aft er adjustment for FISH (HR, 5.72; 95% CI, 1.48-22.05; P =0.01). In contrast, other covariates, which were signifi cant in the univariable analysis were not associated with CCA aft er adjustment for FISH status: prior abnormal FISH or cytology (HR, 0.40; 95% CI 0.40-1.63), CA 19-9 ≥129 U/ml (HR, 1.78; 95% CI, 0.87-3.60), the number of areas sampled when the index FISH was collected (HR, 0.92; 95% CI, 0.55-1.54), dominant stricture (HR, 1.67; 95% CI, 0.85-3.25), atypical cytology (HR, 2.34; 95% CI, 0.68-9.20), serial polysomy (HR, 1.40; 95% CI, 0.46-4.26), and proportion of cells positive for polysomy (HR, 0.92; 95% CI, 0.55-1.54).
Th e remaining 334 patients without CCA were censored at the time of liver transplantation ( n =59) or the last abdominal image or cholangiogram ( n =275). Th e median (IQR) duration of followup among those who remained free of CCA was similar between FISH subgroups: 2.26 (0.78-5.87) years, 3.07 (1.54-5.28) years, 3.06 (1.01-4.73) years, and 1.89 (0.22-3.36) years for negative FISH, trisomy/tetrasomy, UFP, and MFP (respectively). Among the 26 patients with a UFP who were not diagnosed with CCA, eight had serial polysomy and underwent two or more ERCs aft er the index FISH, which did not detect CCA over the course of 2.20 (0.63-4.80) years of follow-up. Similarly, at least two ERCs were performed in those who did not develop serial polysomy aft er a diagnosis of UFP over a course of 1.87 (1.37-3.18) years. Hence it is unlikely that patients with UFP could have harbored an undiagnosed cancer at the time of censoring. Among the eight patients with MFP who were not diagnosed with CCA during this study period, one individual had high-grade dysplasia on a bile duct biopsy. Th e seven other individuals did not have a history of dysplastic bile duct tissue detected on bile duct biopsies. Of these seven patients, one had serial polysomy and suspicious cytology detected and underwent a liver transplant for end-stage liver disease (explant was negative for CCA), while another individual had suspicious cytology and a CA 19-9 of 778 U/ml and died (cause unknown) within a month of MFP detection. Th e median (IQR) duration of follow-up for the remaining fi ve patients was 1.90 (0.32-4.71) years and all fi ve patients underwent at least one ERC since the index FISH.
DISCUSSION
Th is study, the largest published cohort of PSC patients who underwent FISH testing to date, shows for the fi rst time that patients with polysomy detected in multiple sites are more likely to be diagnosed with CCA compared to those with polysomy detected in a single location. Our results also indicate that patients with MFP are more likely to be diagnosed with CCA compared with patients with other FISH fi ndings such as trisomy/tetrasomy and serial polysomy. Indeed, those with MFP were more likely to have a history of weight loss, suspicious cytology, an imaging study suspicious but indeterminate for CCA, or a greater proportion of cells positive for polysomy and serial polysomy when compared with patients with UFP. Our results also illustrate that UFP and suspicious cytology (regardless of the FISH subtype) both remain a concerning fi nding associated with CCA. dominant stricture, all patients died of their disease and had a median survival of 6 months ( 22 ) . Furthermore, the ability for an ERC to distinguish benign from malignant strictures in PSC is limited ( 23 ) . Although a prior study noted an improved diagnostic performance when polysomy was detected in patients with a dominant stricture, many of the patients included in that study had a mass lesion suspicious for CCA at the time of the index FISH ( 14 ) . Th is could increase the probability of having a malignant dominant stricture and would represent a diff erent patient population than the present study, which did not include patients with defi nitive radiographic features of CCA at the time of the index FISH. Th is may be another reason why we did not observe a strong association with CCA and dominant strictures. Hence, these observations and our results suggest that it may be important to brush other areas of the central biliary tree, regardless of whether and where a dominant stricture is present, and place the specimens in separate vials among PSC patients suspected of having CCA but lack defi nitive features on imaging. Insurers such as Medicare have provided reimbursement for this assay ( 15 ) .Future prospective studies should examine the utility and cost-eff ectiveness of this strategy to confi rm whether this approach improves our ability to detect early-stage CCA when bile duct malignancy is suspected in patients with PSC.
Our fi ndings also provide insight into the mechanistic processes of CCA development in PSC patients and lend credence to the hypothesis that CCA arises from a fi eld defect. Field defect is the concept that larger areas of premalignant tissue may extend beyond the primary site of malignancy. Th ese areas are likely to harbor molecular and chromosomal aberrations, but may appear histologically normal. In PSC, CCA develops in a background of chronic biliary tract infl ammation. Chronic infl ammation may mediate CCA development through the induction of DNA damage, enhanced cell proliferation and resistance to apoptosis ( 24, 25 ) . In addition, several studies have suggested that bile duct dysplasia beyond the malignant lesion is common in PSC and there are a greater number of ducts with dysplasia when CCA is present ( 26, 27 ) . Th us, sampling a larger surface area may improve the diagnostic performance of FISH testing, which could enhance our ability to detect MFP and cancer among PSC patients suspected of having CCA.
Our study has several limitations. First, this was a retrospective study conducted at a single academic center that included a select group of PSC patients where a majority of individuals underwent an ERC to evaluate for CCA. Th e selective nature of this cohort is refl ected in the 3-year incidence of CCA for the entire group (11%) when compared with population-based studies, which reported the incidence of CCA among all PSC patients regardless of whether an ERC with FISH testing was performed (10% aft er 8 years) ( 28 ). Consequently, our results should be interpreted in the context of PSC patients where there is a clinical suspicion for underlying CCA and these fi ndings would not be applicable to all PSC patients nor would the evidence support the use of ERC and FISH testing as a universal screening tool. Second, the reporting of a dominant stricture likely varies between practitioners and the inter-observer variability of dominant stricture identifi cation is unknown. Th ird, despite having a large overall sample size, we had a limited number of patients with polysomy and the power of our study is limited by the few number of events. Because of this limitation and the number of comparisons made, our fi ndings should be confi rmed. Last, multiple endoscopists performed the sampling for biliary cytology and FISH specimens during the course of this study. However, the likelihood that sampling bias imaging features at the time of the index FISH, the number of areas brushed and placed in separate vials was similar between those with UFP and MFP and this was included in the multivariable analysis; and (iii) if sample overlap occurred when brushings were obtained from adjacent ductal segments (thereby potentially converting UFP to MFP), it is unlikely this was a signifi cant confounder as we observed numerous diff erences between the MFP and UFP groups, which suggest MFP patients are a high-risk subgroup.
In conclusion, the current study suggests that MFP is a very strong risk factor for CCA among PSC patients suspected of having biliary cancer but lack a mass lesion on imaging at the time of the initial assessment. Patients with MFP may already harbor CCA and patients without other defi nitive features of biliary cancer should have close interval follow-up. Brushing multiple areas of the biliary tree may improve the ability to detect MFP and CCA among a select group of PSC patients and this technique warrants further study. Optimizing the performance of ERC and FISH testing in PSC patients has the potential to facilitate the early diagnosis of CCA, which can in turn expand the pool of patients eligible for curative therapy.
could explain the diff erences observed between the polysomy groups is small for several reasons: (i) the presence and number of dominant strictures was similar between those with UFP and MFP; (ii) although patients with MFP tended to have suspicious Figure 4 . Forest plot illustrating the association of multifocal polysomy, unifocal polysomy, and trisomy/tetrasomy (compared with those with a negative FISH value) with the probability of being diagnosed with cholangio carcinoma after adjusting for other potential risk factors. The fi gure shows the point estimate (hazard ratio) and 95% confi dence interval (CI) of a trisomy/tetrasomy, unifocal, and multifocal polysomy (unadjusted and adjusted for each individual covariate). The cytology adjustment includes two variables representing suspicious cytology vs. negative and atypical cytology vs. negative. A prior history of an abnormal FISH result or cytology included trisomy/tetrasomy or unifocal polysomy (among multifocal polysomy patients) and suspicious or atypical cytology results. Serial polysomy and the proportion of cells with polysomy are excluded from the adjustments since patients with a negative FISH and trisomy/ tetrasomy are unable to have polysomy-specifi c covariates. CA 19-9, carbohydrate antigen 19-9; FISH, fl uorescence in situ hybridization.
